Why some treatments work better than others for myotonic dystrophy type 1
Mechanisms underlying differential efficacy of DM1 therapeutics
This project compares different RNA-targeting therapies to find which approaches are most likely to help people with myotonic dystrophy type 1 (DM1).
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-11161629 on NIH RePORTER |
What this research studies
From my view as a patient, researchers are using a new mouse model that carries very long CTG repeats like those seen in people with DM1 to test three kinds of RNA-targeting drugs (ASOs, siRNAs, and PMOs). The mutant DMPK RNA in the mouse is marked so scientists can track how much bad RNA is made, where it goes in the cell, and how quickly it is cleared. They will compare whether each therapy reduces nuclear RNA foci, restores normal RNA splicing, and improves muscle function. The goal is to find which strategies most reliably correct the molecular and muscle problems that cause DM1 symptoms.
Who could benefit from this research
Good fit: People with a confirmed diagnosis of myotonic dystrophy type 1 (DM1) who are interested in RNA-targeting treatments or future clinical trials would be the relevant patient group.
Not a fit: People without DM1 or with unrelated neuromuscular conditions are unlikely to receive direct benefit from this preclinical research.
Why it matters
Potential benefit: If successful, this work could point doctors and researchers toward the RNA-targeting treatments most likely to help people with DM1 and shape future clinical trials.
How similar studies have performed: Related RNA-targeting approaches have shown promising results in animal studies and some early-phase human trials are beginning, so this work builds on encouraging but still early-stage evidence.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Wang, Eric T — University of Florida
- Study coordinator: Wang, Eric T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.